← Leaderboards
Alice L. Yu
University Of California San Diego
$1,929,330
Attributed
$1,929,330
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $332.2K · FY2005–14$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
FDA$993,660 · 1
NIH$935,670 · 4
By mechanism
R01$1,929,330 · 2
M01$0 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Jane C Burns$14,170,537
- M. Javad Aman$32,287,217
- Bruce A Barshop$109,215
Others in their field
Top investigators on “Pyrimidines”
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Margaret A. Phillips · Ut Southwestern Medical Center$11,432,753
- Richard K. Plemper · Georgia State University$6,660,208
- Aziz Sancar · University Of North Carolina Chapel Hill$6,511,794
- Dieter G Soll · Yale University$5,950,393
- Douglas E Brash · Yale University$5,920,142
Research focus
PyrimidinesUridineClinical ResearchHuman SubjectHuman Therapy EvaluationProdrugsQuality Of LifeRiboseMetabolism DisorderAtaxiaNucleotide MetabolismNeuromuscular FunctionMetabolism Disorder ChemotherapyPurinesEpilepsyEye Coordination DisorderDiet TherapyChild (0-11)CognitionDrug Screening /EvaluationGeneralized SeizuresImmunodeficiencyNervous System InfectionNervous System Disorder Chemotherapy
Grant awards (34)
Predicting toxicity and success of anti-GD2 immunotherapy of neuroblastoma$311,976
R01 · FY2014 · CA · contact PI
Predicting toxicity and success of anti-GD2 immunotherapy of neuroblastoma$302,328
R01 · FY2013 · CA · contact PI
Predicting toxicity and success of anti-GD2 immunotherapy of neuroblastoma$321,366
R01 · FY2012 · CA · contact PI
IMMUNE MONITOR FOR COG TRIAL OF ANTI-GD2 IN NEUROBLASTOMA$332,155
R01 · FY2009 · FD · contact PI
IMMUNE MONITOR FOR COG TRIAL OF ANTI-GD2 IN NEUROBLASTOMA$332,155
R01 · FY2008 · FD · contact PI
IMMUNE MONITOR FOR COG TRIAL OF ANTI-GD2 IN NEUROBLASTOMA$329,350
R01 · FY2007 · FD · contact PI
Immune Monitor-- COG Trial of Anti-GD2 in Neuroblastoma$0
R01 · FY2005 · FD
PYRIMIDINE AND RIBOSE THERAPY IN DISORDERS OF NUCLEOTIDE METABOLISM$0
M01 · FY2002 · RR
PYRIMIDINE AND RIBOSE THERAPY IN DISORDERS OF NUCLEOTIDE METABOLISM$0
M01 · FY2002 · RR
PYRIMIDINE AND RIBOSE THERAPY IN DISORDERS OF NUCLEOTIDE METABOLISM$0
M01 · FY2002 · RR
PYRIMIDINE AND RIBOSE THERAPY IN DISORDERS OF NUCLEOTIDE METABOLISM$0
M01 · FY2002 · RR
PN401 IN PATIENTS W/ PYRIMIDINE RESPONSIVE SYNDROME$0
M01 · FY2002 · RR
PN401 IN PATIENTS W/ PYRIMIDINE RESPONSIVE SYNDROME$0
M01 · FY2002 · RR
PN401 IN PATIENTS W/ PYRIMIDINE RESPONSIVE SYNDROME$0
M01 · FY2002 · RR
PN401 IN PATIENTS W/ PYRIMIDINE RESPONSIVE SYNDROME$0
M01 · FY2002 · RR
ANTIIDIOTYPE MAB FOR ADVANCED STAGE NEUROBLASTOMA$0
M01 · FY2002 · RR
ANTIIDIOTYPE MAB FOR ADVANCED STAGE NEUROBLASTOMA$0
M01 · FY2002 · RR
ANTIIDIOTYPE MAB FOR ADVANCED STAGE NEUROBLASTOMA$0
M01 · FY2002 · RR
ANTIIDIOTYPE MAB FOR ADVANCED STAGE NEUROBLASTOMA$0
M01 · FY2002 · RR
ANTIIDIOTYPE MAB FOR ADVANCED STAGE NEUROBLASTOMA$0
M01 · FY2001 · RR
ANTIIDIOTYPE MAB FOR ADVANCED STAGE NEUROBLASTOMA$0
M01 · FY2001 · RR
PYRIMIDINE AND RIBOSE THERAPY IN DISORDERS OF NUCLEOTIDE METABOLISM$0
M01 · FY2001 · RR
PYRIMIDINE AND RIBOSE THERAPY IN DISORDERS OF NUCLEOTIDE METABOLISM$0
M01 · FY2001 · RR
PN401 IN PATIENTS W/ PYRIMIDINE RESPONSIVE SYNDROME$0
M01 · FY2001 · RR
PN401 IN PATIENTS W/ PYRIMIDINE RESPONSIVE SYNDROME$0
M01 · FY2001 · RR
PN401 IN PATIENTS W/ PYRIMIDINE RESPONSIVE SYNDROME$0
M01 · FY2000 · RR
PYRIMIDINE AND RIBOSE THERAPY IN DISORDERS OF NUCLEOTIDE METABOLISM$0
M01 · FY2000 · RR
PYRIMIDINE AND RIBOSE THERAPY IN DISORDERS OF NUCLEOTIDE METABOLISM$0
M01 · FY2000 · RR
PYRIMIDINE AND RIBOSE THERAPY IN DISORDERS OF NUCLEOTIDE METABOLISM$0
M01 · FY2000 · RR
ANTIIDIOTYPE MAB FOR ADVANCED STAGE NEUROBLASTOMA$0
M01 · FY2000 · RR
ANTIIDIOTYPE MAB FOR ADVANCED STAGE NEUROBLASTOMA$0
M01 · FY2000 · RR
PN401 IN PATIENTS W/ PYRIMIDINE RESPONSIVE SYNDROME$0
M01 · FY2000 · RR
ANTIIDIOTYPE MAB FOR ADVANCED STAGE NEUROBLASTOMA$0
M01 · FY2000 · RR
PN401 IN PATIENTS W/ PYRIMIDINE RESPONSIVE SYNDROME$0
M01 · FY2000 · RR